A5043246394- Virus-based gene therapy research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Viral Infectious Diseases and Gene Expression in Insects
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Protein Degradation and Inhibitors
- Cancer Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Electronic Health Records Systems
- Nanoplatforms for cancer theranostics
- Ubiquitin and proteasome pathways
- Advanced biosensing and bioanalysis techniques
- Immune cells in cancer
- interferon and immune responses
- RNA Interference and Gene Delivery
- Chronic Myeloid Leukemia Treatments
- Hematological disorders and diagnostics
University of Southern California
2022-2025
Abstract Purpose: Our preclinical studies showed that the oncolytic reovirus formulation pelareorep (PELA) has significant immunomodulatory anti-myeloma activity. We conducted an investigator-initiated clinical trial to evaluate PELA in combination with dexamethasone (Dex) and bortezomib (BZ) define tumor immune microenvironment (TiME) patients multiple myeloma treated this regimen. Patients Methods: relapsed/refractory (n = 14) were enrolled a phase Ib (ClinicalTrials.gov: NCT02514382) of...
<div>AbstractPurpose:<p>Our preclinical studies showed that the oncolytic reovirus formulation pelareorep (PELA) has significant immunomodulatory anti-myeloma activity. We conducted an investigator-initiated clinical trial to evaluate PELA in combination with dexamethasone (Dex) and bortezomib (BZ) define tumor immune microenvironment (TiME) patients multiple myeloma treated this regimen.</p>Patients Methods:<p>Patients relapsed/refractory (<i>n</i> = 14)...
<h3>Background</h3> Pelareorep (pela) is an intravenously delivered, non-modified oncolytic reovirus that shows anti-tumor activity through innate and adaptive immune responses as well direct tumor lysis. Previous data from the window of opportunity AWARE-1 study demonstrated synergy between pela in combination with atezolizumab, demonstrating a favorable immunologic response tumors early breast cancer (eBC) patients.<sup>1</sup> To understand complex microenvironment (TME) patients before...
Abstract Background: Pelareorep (pela) is a non-modified intravenously administered oncolytic reovirus exhibiting effective tumor suppression through both innate and adaptive immune responses, as well direct lysis. Findings from the AWARE-1 window of opportunity study previously demonstrated synergistic potential combining pela with atezolizumab (atezo), showcasing promising immunological reactions within tumors early breast cancer (eBC) patients. To gain deeper insights into complex...
<p>Supplementary Figure 1. Induced expression of cytokines, CD69 in lymphocytes, and PD-L1 MM cells with no changes T cell clonality</p>
<p>Supplementary Figure 2. TCR analysis</p>
<p>Supplementary Methods</p>
<p>Supplementary Figure 2. TCR analysis</p>
<p>Supplementary Figure 4. Increased immune cell activity observed by imaging mass cytometry (IMC)</p>
<p>Supplementary Figure 3. Imaging mass cytometry (IMC) staining overview</p>
<p>Supplementary Figure 1. Induced expression of cytokines, CD69 in lymphocytes, and PD-L1 MM cells with no changes T cell clonality</p>